Global Melanoma Cancer Diagnostics Market Surpass a Value US$ 853.5 Million by 2022-end

The global market discussion on melanoma cancer diagnostics industry can be found in the latest study by Fact.MR, which has been freshly added to its massive collection of research database. The report is titled “Melanoma Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Review 2017 to 2022”, which works to enlighten the readers about the major factors prompting the growth of the concerned market. Apart from that, the research majorly focuses on melanoma cancer diagnostics market’s competitive outlook by profiling major players functioning across the globe. As the report moves ahead, information regarding the prominent trends as well as opportunities in the key geographical segments have also been elaborated, thus enabling companies to be able to make region-specific strategies for gaining competitive lead. Some of the prime regions emphasized in the study include key regions.

Request for Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=57

According to a latest market research by fast-growing market research and consulting firm, the global melanoma cancer diagnostics market is poised to grow at over 7% CAGR and surpass US$ 853.5 million in revenues by 2022. Fact.MR’s report forecasts that North America and Europe will remain the most lucrative markets for melanoma cancer diagnostics market globally. Key takeaways from Fact.MR’s report are,

1. The U.S. melanoma cancer diagnostics market will grow at over 7% CAGR and reach US$ 409.2 Mn by 2022. By test type, BRAF mutation segment will continue to be the leading segment.

2. Germany is one of the largest markets for melanoma cancer diagnostics in Europe. Fact.MR projects the Germany melanoma cancer diagnostics market to grow at 7.4% CAGR through 2022. Hospital associated labs are the largest end-users of melanoma cancer diagnostics in Germany. The market in United Kingdom will grow at a higher rate than Germany, but it will be continue to be smaller in market size.

3. The market will be positive influenced by increasing R&D on cancer diagnosis and management. Increasing prevalence of melanoma and effective immunotherapies are expected to drive growth of the market globally.

4. Although the outlook on the global melanoma cancer diagnostics market is positive, limited funds in emerging countries, combined with challenges surrounding regulatory issues can stymie growth during the forecast period.

Analysis by End-Users

By end-users, the key segments of melanoma cancer diagnostics market include hospital associated labs, independent diagnostic laboratories, cancer research institutes, and ‘others’.

The hospital associated labs segment in North America is currently valued at over US$ 137 million, and is expected to grow at a steady CAGR through 2022. The hospital associated labs segment in Europe is anticipated to grow at a significant CAGR through 2022.

Independent diagnostic laboratories end-user segment in North America is expected to surpass US$ 100 million in revenues by 2022, growing at a high single-digit CAGR.

Region-wise Analysis

North America will remain an attractive market for global melanoma cancer diagnostic market. As discussed previously, BRAF mutation will remain the most widely used test type, followed by CTC. Hospital associated labs will continue to be the largest end-users in the North America melanoma cancer diagnostics market.

Europe, the second-largest market for melanoma cancer diagnostics, will continue to offer growth opportunities to manufacturers. By test type, the CTC cancer diagnostics market will continue to grow at highest CAGR, whereas hospital associated labs will be the largest end-users.

Overall, North America and Europe will continue to be the two most lucrative markets for melanoma cancer diagnostics globally.

Competition Tracking

The key companies profiled in the Fact.MR’s report on global melanoma cancer diagnostics market include Foundation Medicine, Inc., Cancer Genetics, Inc., Pathway Genomics Corporation, Abbott Laboratories, and Myriad Genetics Inc.

Browse Full Report with TOC- https://www.factmr.com/report/57/melanoma-cancer-diagnostics-market

Table of Content:

Chapter 1. Global Melanoma Cancer Diagnostics Market – Executive Summary. 20

Chapter 2. Global Melanoma Cancer Diagnostics Market Overview. 22
2.1. Introduction. 22
2.1.1. Global Melanoma Cancer Diagnostics Market Taxonomy. 22
2.1.2. Global Melanoma Cancer Diagnostics Market Definition. 22
2.2. Global Melanoma Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 22
2.2.1. Global Melanoma Cancer Diagnostics Market Y-o-Y Growth. 22
2.3. Global Melanoma Cancer Diagnostics Market Dynamics. 23
2.3.1. Drivers. 23
2.3.2. Restraints. 23
2.3.3. Trends. 23
2.4. Supply Chain. 24
2.5. Epidemiology. 24
2.6. List of Distributors. 24
2.7. Average Pricing Analysis. 24
2.8. Regulations. 25
2.9. Key Participants Market Presence (Intensity Map) By Region. 25

Chapter 3. Global Melanoma Cancer Diagnostics Market Analysis and Forecast By Test Type. 26
3.1. Global Melanoma Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 26
3.1.1. BRAF Mutation Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 26
3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 26
3.1.1.2. Market Share Comparison, By Region. 28
3.1.1.3. Y-o-Y growth Comparison, By Region. 28
3.1.2. CTC Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 29
3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 29
3.1.2.2. Market Share Comparison, By Region. 31
3.1.2.3. Y-o-Y growth Comparison, By Region. 31

Continued….

Check Discount on This Report- https://www.factmr.com/connectus/sample?flag=D&rep_id=57

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com/
Web: https://www.factmr.com/

This release was published on openPR.